MolMed SpA (MLM):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:MolMed SpA (MLM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C7605
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:62
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イタリア
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
MolMed SpA (Molmed) is a biotechnology company which offers research, development, manufacturing and clinical validation of novel anticancer therapies. Its pipeline antitumour products include Zalmoxis (TK), a cell based therapy enabling bone marrow transplants donors for the treatment of high-risk hematological malignancies, eliminating post-transplant immunosuppression prophylaxis, inducing a rapid immune reconstitution; NGR-hTNF, a therapeutic agent showing anti-tumor activity for solid tumors; and CAR-CD44v6, an immuno-gene therapy project for haematological malignancies and several epithelial tumours. The company also conducts cell and gene therapy projects such as development and the validation of the manufacturing process and control strategy, cGMP production of clinical-grade viral vectors and manufacturing of patient-specific genetically engineered cells. Molmed is headquartered in Milano, Italy.

MolMed SpA (MLM) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
MolMed SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
MolMed SpA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
MolMed SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
MolMed SpA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
MolMed SpA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
MolMed SpA, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
MolMed Acquires CAR-CD44v6 Project from San Raffaele Hospital 11
Partnerships 12
MolMed Enters into Development Agreement with GlaxoSmithKline 12
MolMed and AbCheck Enter into Agreement 13
Orchard Therapeutics and MolMed Expand Collaboration Agreement 14
MolMed and Cellectis Enter into Co-Development Agreement 15
MolMed Enters into Agreement with Rocket Pharma 16
MolMed Enters into Co-Development Agreement with Genenta Science 17
MolMed Enters into Agreement with GlaxoSmithKline 18
Licensing Agreements 19
MolMed and Dompe Expand Licensing and Distribution Agreement 19
TTY Biopharm Enters into Licensing Agreement with MolMed 20
Megapharm Enters into Licensing Agreement with MolMed for Zalmoxis 21
Oxford BioMedica Enters into Licensing Agreement with MolMed 22
Equity Offering 23
Molmed Raises USD3.6 Million in Fifth Tranche of Private Placement of Shares 23
MolMed Raises USD6.2 Million in Fourth Tranche of Private Placement of Shares 25
MolMed Raises USD2.2 Million in Second Tranche of Private Placement of Shares 27
MolMed SpA – Key Competitors 28
MolMed SpA – Key Employees 29
MolMed SpA – Locations And Subsidiaries 30
Head Office 30
Other Locations & Subsidiaries 30
Recent Developments 31
Financial Announcements 31
Jul 30, 2018: MolMed approves results at June 30th 2018 31
May 11, 2018: MolMed approves first quarter 2018 results, significantly improved compared to the first quarter 2017 33
Apr 12, 2018: MolMed: the Shareholders’ Meeting approves 2017 Financial Statements 35
Mar 09, 2018: MolMed: Full Year 2017 Results 36
Nov 06, 2017: The Board of Directors Examined the Business Performance and Approved the First Nine Months Financial Report at September 30th, 2017 39
Nov 06, 2017: MolMed Board of Directors examined the business performance and approved the first nine months financial report ended at September 30th, 2017 43
Jul 27, 2017: MolMed Board of Directors reviewed business performance and approved the first half-year financial report ended June 30th, 2017 47
May 08, 2017: MolMed’s Board of Directors reviewed business performance and approved Interim Results at March 31st, 2017 51
Mar 06, 2017: MolMed’s Board of Directors reviewed the business performance and approved the draft financial statements for FY 2016 53
Corporate Communications 57
Sep 24, 2018: MolMed: Carlo Incerti succeeds to Claudio Bordignon as chairman of the board. Salvatore Calabrese appointed officer responsible for the preparation of corporate financial reports 57
Sep 11, 2018: MolMed names Mr. Salvatore Calabrese Chief Financial Officer 59
Jun 29, 2018: MolMed: resignation of the Officer Responsible for the preparation of corporate financial reports 60
Product Approvals 61
Jun 01, 2017: MolMed provides update on Zafiride Conditional Marketing Authorization application 61
Appendix 62
Methodology 62
About GlobalData 62
Contact Us 62
Disclaimer 62

List of Tables
MolMed SpA, Pharmaceuticals & Healthcare, Key Facts, 2017 2
MolMed SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
MolMed SpA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
MolMed SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
MolMed SpA, Deals By Therapy Area, 2012 to YTD 2018 9
MolMed SpA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
MolMed Acquires CAR-CD44v6 Project from San Raffaele Hospital 11
MolMed Enters into Development Agreement with GlaxoSmithKline 12
MolMed and AbCheck Enter into Agreement 13
Orchard Therapeutics and MolMed Expand Collaboration Agreement 14
MolMed and Cellectis Enter into Co-Development Agreement 15
MolMed Enters into Agreement with Rocket Pharma 16
MolMed Enters into Co-Development Agreement with Genenta Science 17
MolMed Enters into Agreement with GlaxoSmithKline 18
MolMed and Dompe Expand Licensing and Distribution Agreement 19
TTY Biopharm Enters into Licensing Agreement with MolMed 20
Megapharm Enters into Licensing Agreement with MolMed for Zalmoxis 21
Oxford BioMedica Enters into Licensing Agreement with MolMed 22
Molmed Raises USD3.6 Million in Fifth Tranche of Private Placement of Shares 23
MolMed Raises USD6.2 Million in Fourth Tranche of Private Placement of Shares 25
MolMed Raises USD2.2 Million in Second Tranche of Private Placement of Shares 27
MolMed SpA, Key Competitors 28
MolMed SpA, Key Employees 29
MolMed SpA, Other Locations 30

List of Figures
MolMed SpA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
MolMed SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
MolMed SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
MolMed SpA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
MolMed SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
MolMed SpA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
MolMed SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
MolMed SpA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[MolMed SpA (MLM):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • VGI Global Media Public Co Ltd:企業の戦略・SWOT・財務情報
    VGI Global Media Public Co Ltd - Strategy, SWOT and Corporate Finance Report Summary VGI Global Media Public Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Northrop Grumman Technical Services Inc.:企業の戦略・SWOT・財務分析
    Northrop Grumman Technical Services Inc. - Strategy, SWOT and Corporate Finance Report Summary Northrop Grumman Technical Services Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT …
  • Chang Chun Petrochemical Co Ltd:企業の戦略的SWOT分析
    Chang Chun Petrochemical Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pro …
  • 3-V Biosciences Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary 3-V Biosciences Inc (3-V Biosciences) is a clinical-stage pharmaceutical company that develops novel therapeutics in metabolic diseases. The company offers TVB-2640, a fatty acid synthase inhibitor used for the treatment of solid tumors, including non-small cell lung cancer (NSCLC), breast c …
  • Polynt SpA:企業の戦略的SWOT分析
    Polynt SpA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …
  • AGL Energy Ltd Oil & Gas Exploration and Production Operations and Cost Analysis – 2017
    AGL Energy Ltd Oil & Gas Exploration and Production Operations and Cost Analysis - 2017 Summary AGL Energy Ltd Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the opera …
  • Premaitha Health Plc (NIPT)-製薬・医療分野:企業M&A・提携分析
    Summary Premaitha Health Plc (Premaitha Health), formerly Vialogy Plc, is a molecular diagnostics company, which focuses on the development of genetic screening tests including novel tests for non-invasive prenatal screening (NIPT). Its flagship product, the IONA test is an advanced NIPT test that a …
  • Rafako SA (RFK):企業の財務・戦略的SWOT分析
    Rafako SA (RFK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • 3D Medicines Corp:製薬・医療:M&Aディール及び事業提携情報
    Summary 3D Medicines Corp (3D Medicines) is a precision medicine company. The company provides cancer precision medical treatment. It offers cancer diagnosis and treatment through the integration of biological characteristics, clinical diagnosis and treatment, and drug research and development data …
  • Kadaster:企業の戦略的SWOT分析
    Kadaster - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Thi …
  • Rehrig Pacific Company:企業の戦略的SWOT分析
    Rehrig Pacific Company - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Copperbelt Energy Corporation Plc (CEC):電力:M&Aディール及び事業提携情報
    Summary Copperbelt Energy Corporation PLC (CEC) is an electric utility that generates, transmits, distributes and sells energy. The company generates electricity from hydro, solar, gas and thermal sources; transmits electricity through a network of transmission lines and high voltage substations and …
  • Mithra Pharmaceuticals SA (MITRA):医療機器:M&Aディール及び事業提携情報
    Summary Mithra Pharmaceuticals SA (Mithra) is a developer and manufacturer of over the counter products and prescription drugs for women’s health and other applications. The company offers products such as estelle, donesta, tibelia, zoreline and myring, among others. Its products are used in the tre …
  • Ganymed Pharmaceuticals AG-製薬・医療分野:企業M&A・提携分析
    Summary Ganymed Pharmaceuticals AG (Ganymed) is a biopharmaceutical company that manufactures and distributes monoclonal antibodies for the treatment of solid cancers. The company conducts clinical trials to manufacture various drug candidates. It also offers antibody cancer drugs and IMABS for mono …
  • Thar Pharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析
    Summary Thar Pharmaceuticals Inc (Thar Pharma), a subsidiary of Grunenthal GmbH is a healthcare solution provider that concentrates on transforming intravenous (IV) drugs into oral drugs for existing and new indications. The company’s lead product T121, an oral form of IV only zoledronic acid, is de …
  • Assembly Biosciences Inc (ASMB):製薬・医療:M&Aディール及び事業提携情報
    Summary Assembly Biosciences Inc (Assembly), formerly Ventrus Biosciences Inc is a biotechnology company that develops, discovers, and commercializes small molecule therapies. The company develops therapies for the treatment of infectious diseases such as microbiotic therapies for Clostridium diffic …
  • FAR Ltd (FAR):石油・ガス:M&Aディール及び事業提携情報
    Summary FAR Ltd (FAR), formerly First Australian Resources NL, is an independent oil and gas company that offers acquisition, exploration, production and development of oil and natural gas properties. The company has oilfield appraisal wells and exploration assets in West and East Africa. It operate …
  • Pfizer Inc.:企業の戦略・SWOT・財務情報
    Pfizer Inc. - Strategy, SWOT and Corporate Finance Report Summary Pfizer Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • ENN Energy Holdings Ltd (2688):企業の財務・戦略的SWOT分析
    ENN Energy Holdings Ltd (2688) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Azimut Exploration Inc (AZM):企業の財務・戦略的SWOT分析
    Summary Azimut Exploration Inc (AEI) is a mining company that offers exploration and development of mineral resources. The company carries out the business of acquisition, exploration, and development of gold, copper, silver, chromium, uranium and rare earth element properties. It also offers projec …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆